Avidity Biosciences, Inc. RNA
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$500 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$498 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$445 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$428 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$428 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$399 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.27MShares$336 Million4.51% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.05MShares$326 Million3.65% of portfolio
-
State Street Corp Boston, MA4.2MShares$194 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.53MShares$163 Million0.17% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.33%
|
$460,000
$46.56 P/Share
|
|
Aug 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.54%
|
$220,000
$22.34 P/Share
|
|
Aug 13
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,542
-3.82%
|
$70,932
$46.66 P/Share
|
|
Aug 13
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,542
+3.68%
|
$9,252
$6.57 P/Share
|
|
Aug 06
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,914
-31.96%
|
$1,298,388
$42.73 P/Share
|
|
Aug 06
2025
|
Eric Mosbrooker Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
130,807
-38.56%
|
$5,755,508
$44.06 P/Share
|
|
Aug 06
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
124,687
+40.16%
|
$1,122,183
$9.05 P/Share
|
|
Aug 06
2025
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
107,500
-84.55%
|
$5,052,500
$47.62 P/Share
|
|
Aug 06
2025
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
107,500
+45.81%
|
$2,365,000
$22.34 P/Share
|
|
Aug 06
2025
|
Troy Edward Wilson Director |
SELL
Open market or private sale
|
Indirect |
65,554
-27.5%
|
$2,949,930
$45.0 P/Share
|
|
Aug 06
2025
|
Troy Edward Wilson Director |
SELL
Open market or private sale
|
Direct |
29,500
-16.91%
|
$1,327,500
$45.0 P/Share
|
|
Aug 06
2025
|
Troy Edward Wilson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,500
+14.14%
|
$354,000
$12.26 P/Share
|
|
Aug 06
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
81,434
-20.37%
|
$3,420,228
$42.74 P/Share
|
|
Aug 06
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,451
+12.01%
|
$616,863
$13.79 P/Share
|
|
Aug 04
2025
|
John B Moriarty Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,245
-4.49%
|
$80,820
$36.21 P/Share
|
|
Jun 17
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
911
-1.78%
|
$27,330
$30.24 P/Share
|
|
Jun 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-19.96%
|
$640,000
$32.88 P/Share
|
|
Jun 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.64%
|
$280,000
$14.22 P/Share
|
|
Jun 10
2025
|
Carsten Boess Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Noreen Henig Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 626K shares |
|---|---|
| Exercise of conversion of derivative security | 800K shares |
| Bona fide gift | 22.5K shares |
| Open market or private sale | 1.24M shares |
|---|---|
| Bona fide gift | 22.5K shares |